Premium
Effect of Non‐Surgical Periodontal Therapy Along With Myo‐Inositol on High‐Sensitivity C‐Reactive Protein and Insulin Resistance in Women With Polycystic Ovary Syndrome and Chronic Periodontitis: A Randomized Controlled Trial
Author(s) -
Tewari Shikha,
Narula Satish Chander,
Singhal Savita Rani,
Sharma Rajinder Kumar
Publication year - 2017
Publication title -
journal of periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.036
H-Index - 156
eISSN - 1943-3670
pISSN - 0022-3492
DOI - 10.1902/jop.2017.170121
Subject(s) - medicine , scaling and root planing , insulin resistance , polycystic ovary , chronic periodontitis , randomized controlled trial , metabolic syndrome , periodontitis , c reactive protein , gastroenterology , anthropometry , homeostatic model assessment , inflammation , insulin , obesity
Background: The purpose of this study is to evaluate the effect of non‐surgical periodontal therapy and medical treatment on the level of a serologic marker of inflammation (high‐sensitivity C‐reactive protein [hsCRP]) and insulin resistance (homeostatic model assessment [HOMA]) in women with polycystic ovary syndrome (PCOS) and chronic periodontitis (CP). Methods: Women with PCOS and CP (n = 60) were randomly divided into two groups. The test group was treated with scaling and root planing (SRP) and myo‐inositol (MI). The control group was treated with MI and given oral hygiene instructions. Anthropometric, metabolic, and periodontal parameters were assessed at baseline and re‐evaluated at 3 and 6 months. All parameters of both groups at 6 months were compared with 25 systemically and periodontally healthy females (group A). Results: Periodontal parameters were significantly improved in the test group compared with the control group at 3‐ and 6‐month follow‐up ( P <0.001). A statistically significant reduction was observed in hsCRP and HOMA in both groups at 3‐ and 6‐month follow‐up ( P <0.05). However, significantly more improvement in hsCRP ( P <0.05) and a statistically comparable reduction in HOMA ( P >0.05) was observed in the test group compared with the control group at 3 and 6 months. Both the test and control group showed significant consistent improvement in metabolic parameters at 3‐ and 6‐month follow‐up, which was further comparable to group A. Conclusion: SRP together with medical treatment results in a greater reduction of systemic inflammatory burden compared with medical treatment alone in management of women with PCOS and CP.